Chun Yee Lau

Sema4 (United States)

Papers

2

Total Citations

145

H-Index

2

About

Chun Yee Lau is a pioneering translational researcher whose work bridges functional genomics and personalized oncology. Her core research focuses on developing innovative, patient-specific drug screening platforms to identify effective treatments for rare and difficult-to-treat cancers. Lau’s major contribution is the creation of a personalized platform using patient-derived organoids (hindgut models) and Drosophila avatars. In her landmark 2019 study (107 citations), she used this platform to identify the combination of trametinib plus zoledronate for a KRAS-mutant metastatic colorectal cancer patient, leading to a strong partial response that remained stable for 11 months. This work demonstrated the power of functional precision medicine for genomically complex tumors. She further extended this approach to adenoid cystic carcinoma (ACC) in a 2021 study (38 citations), where a Drosophila-based screen identified a novel personalized therapy for a patient with this rare, nerve-invasive salivary gland cancer. By combining high-throughput in vivo modeling with clinical application, Lau has established a paradigm for delivering effective treatments to patients with limited options, showcasing how personalized drug screening can directly impact clinical outcomes.

Research Focus

Key Achievements

2
H-Index
2
Papers
145
Total Citations
73
Avg Citations/Paper
🏆 Most Cited Paper
A personalized platform identifies trametinib plus zoledronate for a patient with KRAS-mutant metastatic colorectal cancer
107 citations · 2019
📈 Most Prolific Year: 2019 (1 Papers)
🤝 Key Collaborators: 31
🏛 Institutions: Sema4 (United States)

Top Papers

  1. 1
  2. 2

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 13 days ago